Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age - PubMed (original) (raw)
Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age
B H Kushner et al. J Clin Oncol. 1994 Dec.
Abstract
Purpose: To test the efficacy of a protocol for poor-risk neuroblastoma that builds on the following: (1) our favorable previously reported results with dose-intensive use of cyclophosphamide; (2) our retrospective analysis of neuroblastoma chemotherapy reports, which supported the value of high-dose cisplatin and etoposide (VP-16); and (3) the Goldie-Coldman hypothesis that rapid cytoreduction plus the use of non-cross-resistant chemotherapy combinations will decrease the risk of drug resistance.
Patients and methods: The N6 protocol included seven courses of high-dose chemotherapy plus surgical resection of bulk disease. Courses 1, 2, 4, and 6 consisted of 6-hour intravenous infusions of cyclophosphamide 70 mg/kg/d on days 1 and 2 (ie, 140 mg/kg per course), a 72-hour intravenous infusion of doxorubicin 75 mg/m2 and vincristine 0.1 mg/kg beginning day 1, and vincristine 1.5 mg/m2 intravenous bolus on day 9. Courses 3, 5, and 7 consisted of 2-hour intravenous infusions of VP-16 200 mg/m2/d on days 1 to 3 (ie, 600 mg/m2 per course), and 1-hour intravenous infusions of cisplatin 50 mg/m2/d on days 1 to 4 (ie, 200 mg/m2 per course). Courses were to start after neutrophil counts reached 500/microL and platelet counts reached 100,000/microL. Response was defined by international criteria.
Results: Among 24 consecutive previously untreated patients diagnosed with stage 4 neuroblastoma at more than 1 year of age, 21 patients achieved a complete or very good partial remission; one patient had no evidence of disease except by iodine-131-metaiodobenzylguanidine (MIBG) scan, which was markedly improved; and one patient had resolution of extensive metastatic disease, but still had an incompletely resected primary tumor. The sole patient to have a poor response had clinical features at diagnosis that are atypical for neuroblastoma, namely, 8 years of age and an unknown primary tumor. Severe toxicities included myelosuppression, mucositis, and hearing deficits.
Conclusion: The N6 approach reliably achieves significant cytoreduction against stage 4 neuroblastoma. This may eventuate in an improved cure rate, since consolidative treatments using myeloablative therapy, immunotherapy, or biologic response modifiers such as cis-retinoic acid are most likely to be effective against minimal residual disease.
Similar articles
- N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.
Cheung NK, Kushner BH, LaQuaglia M, Kramer K, Gollamudi S, Heller G, Gerald W, Yeh S, Finn R, Larson SM, Wuest D, Byrnes M, Dantis E, Mora J, Cheung IY, Rosenfield N, Abramson S, O'Reilly RJ. Cheung NK, et al. Med Pediatr Oncol. 2001 Jan;36(1):227-30. doi: 10.1002/1096-911X(20010101)36:1<227::AID-MPO1055>3.0.CO;2-U. Med Pediatr Oncol. 2001. PMID: 11464891 Clinical Trial. - Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.
Kushner BH, Meyers PA, Gerald WL, Healey JH, La Quaglia MP, Boland P, Wollner N, Casper ES, Aledo A, Heller G, et al. Kushner BH, et al. J Clin Oncol. 1995 Nov;13(11):2796-804. doi: 10.1200/JCO.1995.13.11.2796. J Clin Oncol. 1995. PMID: 7595741 Clinical Trial. - NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology.
Coze C, Hartmann O, Michon J, Frappaz D, Dusol F, Rubie H, Plouvier E, Leverger G, Bordigoni P, Béhar C, Beck D, Mechinaud F, Bergeron C, Plantaz D, Otten J, Zucker JM, Philip T, Bernard JL. Coze C, et al. J Clin Oncol. 1997 Dec;15(12):3433-40. doi: 10.1200/JCO.1997.15.12.3433. J Clin Oncol. 1997. PMID: 9396394 Clinical Trial. - Adult medulloblastoma: multiagent chemotherapy.
Greenberg HS, Chamberlain MC, Glantz MJ, Wang S. Greenberg HS, et al. Neuro Oncol. 2001 Jan;3(1):29-34. doi: 10.1093/neuonc/3.1.29. Neuro Oncol. 2001. PMID: 11305414 Free PMC article. Review. - Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma.
Cheung NV, Heller G. Cheung NV, et al. J Clin Oncol. 1991 Jun;9(6):1050-8. doi: 10.1200/JCO.1991.9.6.1050. J Clin Oncol. 1991. PMID: 2033419 Review.
Cited by
- Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes.
Muñoz JP, Larrosa C, Chamorro S, Perez-Jaume S, Simao M, Sanchez-Sierra N, Varo A, Gorostegui M, Castañeda A, Garraus M, Lopez-Miralles S, Mora J. Muñoz JP, et al. Cancers (Basel). 2023 Oct 3;15(19):4837. doi: 10.3390/cancers15194837. Cancers (Basel). 2023. PMID: 37835531 Free PMC article. - Difluoromethylornithine (DFMO) and Neuroblastoma: A Review.
Tangella AV, Gajre AS, Chirumamilla PC, Rathhan PV. Tangella AV, et al. Cureus. 2023 Apr 17;15(4):e37680. doi: 10.7759/cureus.37680. eCollection 2023 Apr. Cureus. 2023. PMID: 37206500 Free PMC article. Review. - Long-term follow-up results of pediatric and adolescent patients with localized Ewing sarcoma treated based on stratified modalities.
Zeng C, Chen T, Wang J, Sun F, Huang J, Lu S, Zhu J, Zhang Y, Sun X, Zhen Z. Zeng C, et al. Cancer Med. 2023 Apr;12(8):9409-9419. doi: 10.1002/cam4.5703. Epub 2023 Feb 21. Cancer Med. 2023. PMID: 36808251 Free PMC article. - Investigation of chemoresistance to first-line chemotherapy and its possible association with autophagy in high-risk neuroblastoma.
Chen T, Zeng C, Li Z, Wang J, Sun F, Huang J, Lu S, Zhu J, Zhang Y, Sun X, Zhen Z. Chen T, et al. Front Oncol. 2022 Oct 20;12:1019106. doi: 10.3389/fonc.2022.1019106. eCollection 2022. Front Oncol. 2022. PMID: 36338726 Free PMC article. - MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment.
Bartolucci D, Montemurro L, Raieli S, Lampis S, Pession A, Hrelia P, Tonelli R. Bartolucci D, et al. Cancers (Basel). 2022 Sep 12;14(18):4421. doi: 10.3390/cancers14184421. Cancers (Basel). 2022. PMID: 36139583 Free PMC article. Review.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical